The NIAID-sponsored trial aimed to determine which of two drug combinations—baricitinib plus remdesivir or dexamethasone plus remdesivir—was more effective.
- Enrollment has closed because the study met pre-defined futility criteria indicating that neither treatment regimen studied is likely significantly better than the other
- Remdesivir is developed by Gilead Sciences; Baricitinib is discovered by Incyte and licensed to Eli Lilly; Dexamethasone is a generic drug
To contact the reporter on this story:
To contact the editor responsible for this story:
© 2021 Bloomberg L.P. All rights reserved. Used with permission.